Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly

被引:152
作者
Yamamoto, K
Takeshita, K
Kojima, T
Takamatsu, J
Saito, H
机构
[1] Nagoya Univ, Dept Transfus Med, Nagoya, Aichi 4668550, Japan
[2] Nagoya Univ, Dept Cardiol, Grad Sch Med, Nagoya, Aichi 4668550, Japan
[3] Nagoya Univ, Dept Med Technol, Sch Hlth Sci, Nagoya, Aichi 4668550, Japan
[4] Nagaya Med Ctr, Nagoya, Aichi 4668550, Japan
关键词
PAI-1; obesity; stress; immune response; vascular remodeling;
D O I
10.1016/j.cardiores.2004.11.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Thrombotic cardiovascular diseases increase in incidence in the elderly, a tendency dependent on the age-related changes in vascular and hemostatic systems that include platelets, coagulation, and fibrinolytic factors as well as in the endothelium. The hypercoagulability of and advanced sclerotic changes in the vascular wall may contribute to the increased incidence of thrombosis in the elderly. One of the important key genes for aging-associated thrombosis is plasminogen activator inhibitor-1 (PAI-1), a principal inhibitor of fibrinolysis. The expression of PAI-1 is not only elevated in the elderly but also significantly induced in a variety of pathologies associated with the process of aging. These conditions include obesity, insulin resistance, emotional stress, immune responses, and vascular sclerosis/remodeling. Several cytokines and hormones, including tumor necrosis factor-alpha, transforming growth factor-beta, angiotensin II, and insulin, positively regulate the gene expression of PAI-1. The recent epidemic in obesity with aging in the industrialized society may heighten the risk for thrombotic cardiovascular disease because adipose tissue is a primary source of PAI-1 and cytokines. Emotional or psychosocial stress and inflammation also cause the elevated expression of PAI-1 in an age-specific pattern. Thus, PAI-1 could play a key role in the progression of cardiovascular aging by promoting thrombosis and vascular (athero)sclerosis. Further studies on the genetic mechanism of aging-associated PAI-1 induction will be necessary to define the basis for cardiovascular aging in relation to thrombosis. (c) 2004 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:276 / 285
页数:10
相关论文
共 50 条
  • [41] Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects
    Al-Hamodi, Zaid
    Ismail, Ikram S.
    Saif-Ali, Riyadh
    Ahmed, Khaled A.
    Muniandy, Sekaran
    CARDIOVASCULAR DIABETOLOGY, 2011, 10
  • [42] Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes
    Birgel, M
    Gottschling-Zeller, H
    Röhrig, K
    Hauner, H
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (06) : 1682 - 1687
  • [43] Evidence for a relationship between plasminogen activator inhibitor-1 and gamma glutamyl transferase
    Bastard, JP
    Bruckert, E
    Porquet, D
    Jardel, C
    Ankri, A
    Delattre, J
    Hainque, B
    THROMBOSIS RESEARCH, 1996, 81 (02) : 271 - 275
  • [44] Intracellular signal transduction modulating expression of plasminogen activator inhibitor-1 in adipocytes
    Goto, D
    Fujii, S
    Kaneko, T
    Furumoto, T
    Sugawara, T
    Zaman, AKMT
    Imagawa, S
    Dong, J
    Nakai, Y
    Mishima, T
    Sobel, BE
    Kitabatake, A
    BIOCHEMICAL PHARMACOLOGY, 2003, 65 (11) : 1907 - 1914
  • [45] BODY-COMPOSITION AND WEIGHT-REDUCTION IN RELATION TO ANTIGEN AND ACTIVITY OF PLASMINOGEN-ACTIVATOR INHIBITOR (PAI-1) IN OVERWEIGHT INDIVIDUALS
    HUISVELD, IA
    LEENEN, R
    VDKOOY, K
    HOSPERS, JEH
    SEIDELL, JC
    DEURENBERG, P
    KOPPESCHAAR, HPF
    MOSTERD, WL
    BOUMA, BN
    FIBRINOLYSIS, 1990, 4 : 84 - 85
  • [46] Changes in the plasma level of plasminogen activator inhibitor-1 in patients with cranio-cerebral trauma depending on body weight and PAI-1 -675 4G/5G gene polymorphism
    Potapov, O. O.
    Kmyta, O. P.
    Tsyndrenko, O. O.
    Khavro, M. P.
    Bereznyi, T., V
    Karpeko, I. O.
    ZAPOROZHYE MEDICAL JOURNAL, 2019, (01) : 44 - 48
  • [47] On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice
    Lijnen, HR
    Alessi, MC
    Van Hoef, B
    Collen, D
    Juhan-Vague, I
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (06) : 1174 - 1179
  • [48] PLASMINOGEN-ACTIVATOR INHIBITOR-1 AND INSULIN LEVELS IN VARIOUS INSULIN RESISTANCE STATES
    SCELLES, V
    RACCAH, D
    ALESSI, MC
    VIALLE, JM
    JUHANVAGUE, I
    VAGUE, P
    DIABETES & METABOLISM, 1992, 18 (01) : 38 - 42
  • [49] INSULIN SENSITIVITY IS NOT AN INDEPENDENT DETERMINANT OF PLASMA PLASMINOGEN-ACTIVATOR INHIBITOR-1 ACTIVITY
    MYKKANEN, L
    RONNEMAA, T
    MARNIEMI, J
    HAFFNER, SM
    BERGMAN, R
    LAAKSO, M
    ARTERIOSCLEROSIS AND THROMBOSIS, 1994, 14 (08): : 1264 - 1271
  • [50] Role of plasminogen activator inhibitor-1 in glucocorticoid-induced muscle change in mice
    Tamura, Yukinori
    Kawao, Naoyuki
    Shimoide, Takeshi
    Okada, Kiyotaka
    Matsuo, Osamu
    Kaji, Hiroshi
    JOURNAL OF BONE AND MINERAL METABOLISM, 2018, 36 (02) : 148 - 156